ClinicalTrials.gg
Not yet recruitingNCT06530810Updated Jul 31, 2024

Study of HS-10382 Combination in Patients With Chronic Myeloid Leukemia (CML)

A Phase 1 interventional study of HS-10382+Flumatinib in Chronic Myelogenous Leukemia, CML Chronic Phase and CML Accelerated Phase, sponsored by Jiangsu Hansoh Pharmaceutical Co., Ltd.. Not yet recruiting. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-07-31.

Sponsored by Jiangsu Hansoh Pharmaceutical Co., Ltd. (part of Hansoh Pharmaceutical Group Company Limited) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by May 2026, 6 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
100
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Study summary

HS-10382 is a small molecular, oral potent, allosteric inhibitor. By binding a myristoyl site of the BCR-ABL1 protein, HS-10382 locks BCR-ABL1 into an inactive conformation. Flumatinib is the first approved second generation TKI in China and a derivative of imatinib.

The primary objective of this study is to evaluation the safety and tolerability and of HS-10382 combination therapy in patients with chronic myeloid leukemia (CML).

The secondary objectives is to evaluate the PK profile, major metabolites and efficacy of HS-10382 in CML-CP/AP subjects after combination therapy, and to explore the kinase domain mutations associated with TKI resistance

02

Conditions studied

  • Chronic Myelogenous Leukemia
  • CML Chronic Phase
  • CML Accelerated Phase

Keywords

  • CML-CP/AP
  • HS-10382
  • Flumatinib
  • Allosteric inhibitor
03

In context

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

894 studies on the registry are indexed under Leukemia, Myelogenous, Chronic, BCR-ABL Positive; 109 are open to participants now.

This study's planned enrollment of 100 is above the median of 44 across 681 interventional studies indexed under Leukemia, Myelogenous, Chronic, BCR-ABL Positive.

Browse Leukemia, Myelogenous, Chronic, BCR-ABL Positive studies →

Lead sponsor

Jiangsu Hansoh Pharmaceutical Co., Ltd. is the lead sponsor of 138 studies on the registry; 72 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed form.
  • Men or women aged more than or equal to (≥) 18 years, and less than (\<) 75 years.
  • CML-CP/AP patients with the Ph chromosome or BCR-ABL1 fusion genes.
  • Patient with CML-CP/AP who are resistant to or intolerant to previous TKIs therapy.
  • performance status of 0-1 and no worsening within 2 weeks before the first dose.
  • ≥ 12 weeks.
  • Men or women should be using adequate measures throughout the study; Females should not be breastfeeding at the time of screening, during the study and until 6 months after completion of the study.
  • Females must have evidence of non-.

Exclusion criteria

Exclusion Criteria:

  • CML-CP patients who have acquired CCyR and have not lost it.
  • Patients with CML-CP who have progressed to AP or blast phase(BP.)
  • Patients with CML-AP who have obtained CHR or no evidence of CML in peripheral blood.
  • Patients with CML-AP who have progressed to BP.
  • Previous treatment with a BCR-ABL1 TKI allosteric inhibitor .
  • Impaired cardiac function including any one of the following:
  • Resting interval (QTc) > 470 ms obtained from (ECG), using the screening clinic's ECG machine and Fridericia's formula for QT interval correction (QTcF).
  • Any abnormalities in rhythm, conduction, or morphology of the resting ECG.
  • Any factors that increase the risk of QTc prolongation or risk of arrhythmic events,
  • (LVEF) ≤ 50%.
  • Myocardial infarction occurred within 6 months of the first scheduled dose of study drug.;
  • Congestive heart failure occurred within 6 months of the first scheduled dose of study drug.;
  • Uncontrollable angina.
  • History of acute pancreatitis within 1 year of study entry or past medical history of chronic pancreatitis
  • Any severe or uncontrolled systemic diseases (i.e. uncontrolled hypertension or diabetes).
  • Clinically severe gastrointestinal dysfunction that may affect drug intake, transport or absorption.
  • Severe infection within 4 weeks prior to the first scheduled dose of study drug
  • Inadequate other organ function.
  • History of other .
  • History of to any active or inactive ingredient of HS-10382 and flumatinib.
  • History of neuropathy or mental disorders, including epilepsy and dementia.
  • Judgment by the investigator that the patient should not participate in the study if the patient is unlikely to comply with study procedures, restrictions, and requirements
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    HS-10382+Flumatinib

    Subjects with resistant or intolerant CML CP/AP will be enrolled in dose-escalation stage.Dose escalation of HS-10382 combined flumatinib will be done to determine maximum tolerated dose(Part 1). Depending on data obtained from the dose-escalation stage,dose expansion may proceed with in subjects with newly diagnosed CML-CP.The safety and efficacy will be evaluated at the target dose.(Part 2)

    Drug: HS-10382+Flumatinib

Interventions

  • DrugHS-10382+Flumatinib

    Drug pages: Embibatinib · Flumatinib

    Drug:HS-10382+Flumatinib HS-10382 is administered orally BID Drug:Flumatinib Flumatinib 400mg once daily

06

What researchers measure

Primary outcomes

  1. Maximum tolerated dose (MTD) for HS-10382 combined treatment

    MTD was defined as the previous dose level at which 2 out of 3 subjects or 2 out of 6 subjects experienced a DLT

    Time frame: Up to day 28 from the first dose

Secondary outcomes

  1. Incidence and severity of treatment-emergent adverse events

    Assessed by number and severity of adverse events as recorded on the case report form, vital signs, laboratory variables, physical examination, electrocardiogram, and NCI CTCAE v5.0

    Time frame: Cycle 1 day 1 up to 28 days after the last dose

  2. maximum plasma concentration of HS-10382 or Flumatinib(and its major metabolite ) after HS-10382 combination therapy

    Cmax is the maximum observed concentration.

    Time frame: Cycle 1 day 1 up to 28 days after the last dose

  3. Time to reach maximum plasma concentration of HS-10382 or Flumatinib(and its major metabolite) after HS-10382 combination therapy

    Tmax is defined as time to reach maximum observed plasma concentration

    Time frame: Cycle 1 day 1 up to 28 days after the last dose

  4. half-life (T1/2) of HS-10382 combination therapy

    half-life is the time measured for the concentration to decrease by one half

    Time frame: Cycle 1 day 1 up to 28 days after the last dose

  5. Area under the curve (AUC) of HS-10382 combination therapy

    The AUC is defined as the area under the plasma concentration-time curve

    Time frame: Cycle 1 day 1 up to 28 days after the last dose

  6. Hematologic Response of combination therapy with HS-10382

    To record and analyse the hematologic response of subjects. Hematologic response will be assessed by complete blood count (CBC) and physical examination at each visit.

    Time frame: up to 24 months

  7. Cytogenetic Response of combination therapy with HS-10382

    To record and analyse the cytogenetic response of subjects. Cytogenetic response (CyR) is based on the prevalence of Ph+ cells in metaphase from bone marrow (BM) sample.

    Time frame: up to 24 months

  8. Molecular Response of combination therapy with HS-10382

    To record and analyse the molecular response of subjects. Molecular response will be assessed by BCR-ABL1 transcript level as measured by RQ-PCR.

    Time frame: up to 24 months

  9. Event-free survival (EFS)

    EFS is defined as the time from the date of first dose to the earliest occurrence of the following events: death due to any cause ; loss of CHR ,loss of PCyR ;loss of CCyR ; discontinuation of study treatment due to AE or treatment failure ; progression to AP/BC .

    Time frame: up to 24 months

  10. Progression-free survival (PFS)

    PFS is defined as the time from the date of first dose to the earliest occurrence of progression to AP/BC or death from any cause.

    Time frame: From the first dose to disease progression or withdrawal from study, whichever came first,up to 24 months

  11. Overall survival (OS)

    OS is defined as the time from the date of first dose to the date of death from any cause.

    Time frame: From the first dose up to death or withdrawal from study, whichever came first, up to 24 months

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jul 2024; primary completion for May 2026, 21 months later.

Of 56 phase 1 interventional studies under Leukemia, Myelogenous, Chronic, BCR-ABL Positive, half reached primary completion within 58 months of starting (the median), counting those still running; a quarter within 41 and three quarters within 95. This study's planned 21 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 19, 2024
First posted
Jul 31, 2024
StartEst.
Jul 31, 2024
Primary completionEst.
May 8, 2026
CompletionEst.
May 8, 2028
Last update
Jul 31, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 31, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06530810
Responsible party
Sponsor
First posted
Jul 31, 2024
Start date
Jul 31, 2024 (estimated)
Primary completion
May 8, 2026 (estimated)
Completion
May 8, 2028 (estimated)
Last update
Jul 31, 2024

Study contacts

Yu Hu, PhD
Contact
dr_huyu@126.com
13986183871

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Embibatinib · Flumatinib

Start the discussion